Recce awarded $US 2 million grant to develop burn treatment for military

Recce Pharmaceuticals has been awarded a grant of US$2 million (approximately $3 million) by the US Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) for development of burn wound treatments.

Recce, an ASX-listed company developing synthetic anti-infectives, said in a statement on Monday morning (AEST) that the grant recognised its RECCE 327 Gel (R327G) as a topical treatment for burn wound infections. 

The project’s main aim is to establish the potential of the gel in point-of-injury use by the military, and would evaluate it “to rapidly resolve burn wound infections and minimise the onset of bacteraemia complications, such as sepsis.”

Recce CEO James Graham said “This recognition is  a testament to the unique profile of Recce technology and the high quality of R&D conducted. 

“We look forward to working closely with the US Department of Defense to progress our research efforts and fulfil our commitment to improving global health outcomes.” 

The news follows an announcement last week that Recce had received commitments to raise $8.0 million via an institutional placement to support clinical trials for intravenous use of R327 and topical applications of R327G. 

Recce said on Monday that the placement had been completed, with an opened share purchase plan to raise up to $2 million available until July 31. 

According to its website, Recce is developing three formulations of anti-infectives “to address the urgent global health threat posed by superbugs”.

Picture: credit Recce Pharmaceuticals

Further reading

Recce Pharmaceuticals to test for burn healing

RECCE uses innovative method to bring forward R&D incentive

Manufacturing news briefs — stories you might have missed